← Back to Search

Tyrosine Kinase Inhibitor

Dasatinib for Mesothelioma

Phase 1
Waitlist Available
Led By Anne S. Tsao, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years, or until disease progression.
Awards & highlights

Study Summary

This trial is studying dasatinib and how it affects biomarkers in patients with mesothelioma that may be able to be removed by surgery. It will also look at the safety and effectiveness of the drug.

Eligible Conditions
  • Mesothelioma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years, or until disease progression.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years, or until disease progression. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Modulation of biomarker p-Src Tyr419 expression
Secondary outcome measures
Progression-free Survival

Side effects data

From 2022 Phase 2 trial • 54 Patients • NCT03023046
26%
Febrile neutropenia
17%
Sepsis
9%
Mucositis oral
4%
Upper gastrointestinal hemorrhage
4%
Intracranial hemorrhage
4%
Hypotension
4%
Hypertension
4%
Enterocolitis
2%
Lower gastrointestinal hemorrhage
2%
Delirium
2%
Oropharyngeal pain
2%
Gastric hemorrhage
2%
Abdominal pain
2%
Diarrhea
2%
Fungemia
2%
Typhlitis
2%
Myocardial infarction
2%
Fibrinogen decreased
2%
Endophthalmitis
2%
Multi-organ failure
2%
Kidney infection
2%
Peripheral motor neuropathy
2%
Hypoxia
2%
Sinus bradycardia
2%
Edema limbs
2%
Small intestinal obstruction
2%
Atrial fibrillation
2%
Aspiration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Chemotherapy)

Trial Design

1Treatment groups
Experimental Treatment
Group I: DasatinibExperimental Treatment1 Intervention
Dasatinib = BMS-354825, Sprycel
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dasatinib
2012
Completed Phase 3
~2320

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,965 Previous Clinical Trials
1,804,861 Total Patients Enrolled
12 Trials studying Mesothelioma
572 Patients Enrolled for Mesothelioma
Bristol-Myers SquibbIndustry Sponsor
2,634 Previous Clinical Trials
4,126,799 Total Patients Enrolled
14 Trials studying Mesothelioma
1,888 Patients Enrolled for Mesothelioma
United States Department of DefenseFED
859 Previous Clinical Trials
225,442 Total Patients Enrolled
3 Trials studying Mesothelioma
340 Patients Enrolled for Mesothelioma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dasatinib in Resectable Malignant Pleural Mesothelioma
2008. "Dasatinib in Resectable Malignant Pleural Mesothelioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00652574.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top